AmbioPharm Completes Expansion of Its Shanghai Manufacturing Site

(North Augusta, SC) – AmbioPharm, a leading global peptide contract development and manufacturing organization (CDMO), has completed the expansion of its manufacturing site in Shanghai. The newly finished facility enhances the company’s global capacity and strengthens support for partners advancing complex peptide therapies toward clinical and commercial milestones.

The expanded site adds large-scale GMP manufacturing lines and greater operational flexibility for late-stage programs. The site integrates seamlessly with AmbioPharm’s U.S. operations, enabling efficient technology transfer that supports business continuity and long-term partner needs.

A short video showcasing the expanded site is available here:

About AmbioPharm  

AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.